| 08-Sep-2026 |
16.61 |
-0.27 {-1.6 %} |
V: 4,394,505 |
|
| VTRS |
08-Sep-2026 |
Close: 16.61 |
-0.27 {-1.6 %} |
Volume: 4,394,505 |
|
|
|
|
|
|
|
|
16-Jul-2026
18-Jun-2026
29-Aug-2025
30-Jun-2022
|
|
|
|
|
|
VTRS
|
SPY
|
|
-1.6
-1.6
0.6
4.6
33.4
|
-0.5
-0.5
-0.1
2.6
12.3
|
|
% Price Gain
WTD Performance (%)
MTD Performance (%)
QTD Performance (%)
YTD Performance (%)
|
SPY tracks S&P 500 index.
|
|
15 minute intraday candlestick chart, ~15 minute delay
15 minute intraday candlestick chart, ~15 minute delay
|
| VTRS News | 31-Aug-2026 - Yahoo Finance
VIATRIS INC (VTRS.VI) Q1 FY2026 earnings call transcript
Viatris delivered Q1 2026 revenue of $3.5B, up 3% year-over-year, with adjusted EBITDA of $1B (10% growth) and adjusted EPS of $0.59. Management reaffirmed full-year guidance, citing strong China ... | 10-Aug-2026 - Yahoo Finance
VTRS Q2 Deep Dive: China Growth, Pipeline Progress, and Margin Concerns Shape Outlook
Medication company Viatris (NASDAQ:VTRS) announced better-than-expected revenue in Q2 CY2026, with sales up 4.9% year on year ... | 7-Aug-2026 - The Globe and Mail
Viatris (NASDAQ:VTRS) Posts Better-Than-Expected Sales In Q2 CY2026
Medication company Viatris (NASDAQ:VTRS) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 4.9 ... | 7-Aug-2026 - StockStory.org
VTRS Q2 deep dive: China growth, pipeline progress, and margin concerns shape outlook
Medication company Viatris (NASDAQ:VTRS) announced in Q2 CY2026, with sales up 4.9% year on year to $3.76 billion. The ... | 6-Aug-2026 - Benzinga
Viatris sharpens focus with divestiture, hikes 2026 outlook
Harrow Inc. HROW on Thursday agreed to acquire Tyrvaya (varenicline solution) nasal spray 0.03 mg from Viatris Inc. VTRS. | 6-Aug-2026 - Morningstar
Viatris Looks to New Launches, Pipeline Progression, and Cost Savings for Long-Term Growth
Viatris is one of the largest generic drug manufacturers in the world. Generic drugs make up about 35% of the company's sales. Generics continue to suffer annual low- to mid-single-digit erosion in ... | 6-Aug-2026 - Zacks Investment Research
VTRS Q2 earnings beat, revenues rise 5% as Greater China sales jump
Viatris VTRS delivered second-quarter 2026 adjusted earnings per share of 69 cents, which beat the Zacks Consensus Estimate ... | 6-Aug-2026 - Seeking Alpha
Viatris posts Q2 beat; sells eye drug Tyrvaya to Harrow for up to $100M
Viatris (VTRS) stock is in focus as the company beats Street forecasts with Q2 2026 financials and plans to sell Tyrvaya rights to Harrow (HROW). Read more here. | 6-Aug-2026 - Yahoo Finance
Viatris (VTRS) Beats Q2 Earnings and Revenue Estimates
Viatris (VTRS) delivered earnings and revenue surprises of +11.29% and +2.19%, respectively, for the quarter ended June 2026. | | | |
|
Latest VTRS Trades by Congress Members
|
18-NOV-2025 - Gilbert Cisneros, CA (District 31) purchased between $1,001 and $15,000.
THIS TRADE WAS FILED 15-DEC-2025.
|
8-APR-2025 - Rob Bresnahan, PA (District 8) sold between $1,001 and $15,000.
THIS TRADE WAS FILED 8-MAY-2025.
|
31-MAR-2025 - Gilbert Cisneros, CA (District 31) sold some (partial sale) valued between $1,001 and $15,000.
THIS TRADE WAS FILED 7-APR-2025.
|
25-FEB-2025 - Rob Bresnahan, PA (District 8) purchased between $1,001 and $15,000.
THIS TRADE WAS FILED 27-MAR-2025.
|
|
Latest VTRS Trades by Congress Members
|
18-NOV-2025 - Gilbert Cisneros, CA (District 31) purchased between $1,001 and $15,000.
THIS TRADE WAS FILED 15-DEC-2025.
|
8-APR-2025 - Rob Bresnahan, PA (District 8) sold between $1,001 and $15,000.
THIS TRADE WAS FILED 8-MAY-2025.
|
31-MAR-2025 - Gilbert Cisneros, CA (District 31) sold some (partial sale) valued between $1,001 and $15,000.
THIS TRADE WAS FILED 7-APR-2025.
|
25-FEB-2025 - Rob Bresnahan, PA (District 8) purchased between $1,001 and $15,000.
THIS TRADE WAS FILED 27-MAR-2025.
|
|
|
|
Disclaimer
Privacy
Contact
Copyright © 2001-2026, All rights reserved.
HotCandlestick.com, LLC
|
